Asthma & Chronic obstructive pulmonary disease (COPD) 2017
In-Person Event
Mar 29 - 30, 2017
London, England, GBSpeakers
OVERVIEW
Asthma & COPD 2017 is organized by SMi Group and would be held during Mar 29 - 30, 2017 at Holiday Inn London - Kensington Forum, London, England, United Kingdom.
The target audience for this medical event for senior scientists, principle scientists, associate directors, managing directors, medical directors, pharmaceutical experts, inhalation toxicologists of the following departments clinical pharmacology, respiratory medicine, respiratory immunology, pulmonary specialty, respiratory physiology.
Aimed at senior scientists and respiratory and inhalation specialists, Asthma & COPD 2017 will reflect on the ongoing issues and latest developments of these two diseases.
With a carefully selected panel of industry experts, the 2017 event will address the latest challenges and changes in the fields of asthma and COPD. The agenda will explore novel approaches to treatment, including cutting edge developments in triple combination therapies and phenotyping. As well as identify challenges to device development and delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.
Featured Speakers :
Quan Yang, Pharmaceutical Assessor, MHRA
Stephen Beckman, Head of Global Respiratory and Allergy, Mylan
Outi Vaarala, Vice President, Head of Translational Biology, AstraZeneca
Ewan Walters, Medical Director, Teva UK
David Leather, Global Medical Affairs Leader, GlaxoSmithKline
Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals
Christopher Stevenson, Venture Leader COPD Interception, Janssen
Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca
Frank Thielmann, Operational Lead Inhalation New Solids, Novartis
and many more
Exclusive highlights in 2016 :
• Updates from the MHRA on the regulatory challenge to developing inhalation devices
• Overcome hurdles to the success of new devices with Boehringer Ingelheim
• Janssen's innovative approaches to COPD interception
• Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune
• Real time data collection - an exclusive case study presentation on GSK's pioneering Salford Lung study
WORKSHOPS :
Both interactive workshops have been carefully selected to complement the topics covered in the conference agenda.
Price :
Standard: GBP 1499
Standard by 30/11/2016: GBP 1099
Standard by 16/12/2016: GBP 1299
Standard by 31/01/2016: GBP 1399
WORKSHOP A: GBP 599
WORKSHOP B: GBP 599
The target audience for this medical event for senior scientists, principle scientists, associate directors, managing directors, medical directors, pharmaceutical experts, inhalation toxicologists of the following departments clinical pharmacology, respiratory medicine, respiratory immunology, pulmonary specialty, respiratory physiology.
Aimed at senior scientists and respiratory and inhalation specialists, Asthma & COPD 2017 will reflect on the ongoing issues and latest developments of these two diseases.
With a carefully selected panel of industry experts, the 2017 event will address the latest challenges and changes in the fields of asthma and COPD. The agenda will explore novel approaches to treatment, including cutting edge developments in triple combination therapies and phenotyping. As well as identify challenges to device development and delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.
Featured Speakers :
Quan Yang, Pharmaceutical Assessor, MHRA
Stephen Beckman, Head of Global Respiratory and Allergy, Mylan
Outi Vaarala, Vice President, Head of Translational Biology, AstraZeneca
Ewan Walters, Medical Director, Teva UK
David Leather, Global Medical Affairs Leader, GlaxoSmithKline
Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals
Christopher Stevenson, Venture Leader COPD Interception, Janssen
Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca
Frank Thielmann, Operational Lead Inhalation New Solids, Novartis
and many more
Exclusive highlights in 2016 :
• Updates from the MHRA on the regulatory challenge to developing inhalation devices
• Overcome hurdles to the success of new devices with Boehringer Ingelheim
• Janssen's innovative approaches to COPD interception
• Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune
• Real time data collection - an exclusive case study presentation on GSK's pioneering Salford Lung study
WORKSHOPS :
Both interactive workshops have been carefully selected to complement the topics covered in the conference agenda.
Price :
Standard: GBP 1499
Standard by 30/11/2016: GBP 1099
Standard by 16/12/2016: GBP 1299
Standard by 31/01/2016: GBP 1399
WORKSHOP A: GBP 599
WORKSHOP B: GBP 599
KEY DATES
29 Mar, 2017
Event Start Date
30 Mar, 2017
Event End Date
SPECIALITIES
Pharmacy and MedicineSUGGESTED HOTELS
CONFERENCE VENUE
Holiday Inn London - Kensington ForumRELATED CONFERENCES & LIVE WEBINARS
Quick Links